{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:55Z","timestamp":1761519115834,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.4158\/ep14396.ra","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T21:05:26Z","timestamp":1424898326000},"page":"645-667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of Insulin Sensitizers on Cardiovascular Risk Factors in Polycystic Ovarian Syndrome: A Meta-Analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Tina K.","family":"Thethi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie","family":"Katalenich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prathima","family":"Nagireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankdeep","family":"Chabbra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitesh Kuhadiya","family":"MD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP14396.RA_bb0010","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0015","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0020","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jcem.84.11.6148","article-title":"A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile","volume":"84","author":"Diamanti-Kandarakis","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0025","first-page":"2434","article-title":"A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain","volume":"85","author":"Asunci\u00f3n","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0030","first-page":"3078","article-title":"Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study","volume":"83","author":"Knochenhauer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0035","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1056\/NEJM199806253382603","article-title":"Effects of metformin on spontaneous and clomipheneinduced ovulation in the polycystic ovary syndrome","volume":"338","author":"Nestler","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14396.RA_bb0040","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/bmj.297.6655.1024","article-title":"Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome","volume":"297","author":"Homburg","year":"1988","journal-title":"BMJ"},{"key":"10.4158\/EP14396.RA_bb0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dml036","article-title":"A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome","volume":"12","author":"Boomsma","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.4158\/EP14396.RA_bb0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.22.1.141","article-title":"Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome","volume":"22","author":"Ehrmann","year":"1999","journal-title":"Diabetes Care"},{"key":"10.4158\/EP14396.RA_bb0055","first-page":"165","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women","volume":"84","author":"Legro","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0895-4356(98)00010-9","article-title":"Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study","volume":"51","author":"Talbott","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.4158\/EP14396.RA_bb0065","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9343(01)00948-2","article-title":"Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome","volume":"111","author":"Legro","year":"2001","journal-title":"Am J Med"},{"key":"10.4158\/EP14396.RA_bb0070","first-page":"3389","article-title":"Altered composition of high density lipoproteins in women with the polycystic ovary syndrome","volume":"82","author":"Rajkhowa","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jc.2006-1705","article-title":"Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome","volume":"92","author":"Berneis","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/jc.2005-2430","article-title":"Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome","volume":"91","author":"Lo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 2","key":"10.4158\/EP14396.RA_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000181560","article-title":"Impaired glucose tolerance in patients with polycystic ovary syndrome (PCOS)","volume":"33","author":"Kinoshita","year":"1990","journal-title":"Horm Res"},{"key":"10.4158\/EP14396.RA_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-006-0241-0","article-title":"Glucose intolerance in Japanese patients with polycystic ovary syndrome","volume":"275","author":"Kurioka","year":"2007","journal-title":"Arch Gynecol Obstet"},{"key":"10.4158\/EP14396.RA_bb0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0015-0282(16)57297-5","article-title":"Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome","volume":"63","author":"Norman","year":"1995","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF03345554","article-title":"The metabolic syndrome in polycystic ovary syndrome","volume":"29","author":"Essah","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP14396.RA_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1071\/R98010","article-title":"Obesity and reproductive disorders: a review","volume":"10","author":"Norman","year":"1998","journal-title":"Reprod Fertil Dev"},{"key":"10.4158\/EP14396.RA_bb0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diabetes.47.5.699","article-title":"The metabolically obese, normal-weight individual revisited","volume":"47","author":"Ruderman","year":"1998","journal-title":"Diabetes"},{"key":"10.4158\/EP14396.RA_bb0115","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2004-1045","article-title":"Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome","volume":"90","author":"Apridonidze","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1043-2760(02)00612-4","article-title":"The role of lifestyle modification in polycystic ovary syndrome","volume":"13","author":"Norman","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0125","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0130","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14396.RA_bb0135","first-page":"1470","article-title":"Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone","volume":"84","author":"Huber-Buchholz","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0140","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0889-8545(05)70157-1","article-title":"Insulin-lowering medications in polycystic ovary syndrome","volume":"27","author":"Taylor","year":"2000","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.4158\/EP14396.RA_bb0145","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"10.4158\/EP14396.RA_bb0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.4158\/EP14396.RA_bb0155","first-page":"1694","article-title":"Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome","volume":"28","author":"Qublan","year":"2007","journal-title":"A prospective comparative study. Saudi Med J"},{"key":"10.4158\/EP14396.RA_bb0160","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1210\/jc.2007-0441","article-title":"Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome","volume":"92","author":"Palomba","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.fertnstert.2006.11.173","article-title":"N-acetyl cysteine vs. metformin in treatment of clomiphene citrateresistant polycystic ovary syndrome: a prospective randomized controlled study","volume":"88","author":"Elnashar","year":"2007","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0170","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.fertnstert.2006.05.061","article-title":"Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study","volume":"87","author":"Rautio","year":"2007","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0175","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2005-2250","article-title":"Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study","volume":"91","author":"Gambineri","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1471-0528.2006.00966.x","article-title":"The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial","volume":"113","author":"Lord","year":"2006","journal-title":"BJOG"},{"key":"10.4158\/EP14396.RA_bb0185","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/humrep\/dei505","article-title":"Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebocontrolled study","volume":"21","author":"Rautio","year":"2006","journal-title":"Hum Reprod"},{"key":"10.4158\/EP14396.RA_bb0190","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/JPEM.2005.18.8.761","article-title":"Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome","volume":"18","author":"Allen","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/humrep\/dei311","article-title":"Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study","volume":"21","author":"Tang","year":"2006","journal-title":"Hum Reprod"},{"key":"10.4158\/EP14396.RA_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/humrep\/dei312","article-title":"Rosiglitazone and ethinyl estradiol\/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance","volume":"21","author":"Lemay","year":"2006","journal-title":"Hum Reprod"},{"key":"10.4158\/EP14396.RA_bb0205","first-page":"194","article-title":"Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome","volume":"25","author":"Lv","year":"2005","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.4158\/EP14396.RA_bb0210","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.1.01840","article-title":"Effects of metformin and ethinyl estradiolcyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome","volume":"152","author":"Rautio","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP14396.RA_bb0215","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09513590400004736","article-title":"Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study","volume":"19","author":"Sahin","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"10.4158\/EP14396.RA_bb0220","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1210\/jc.2004-0176","article-title":"Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome","volume":"90","author":"Jayagopal","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0225","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1590\/S0100-879X2004001100007","article-title":"Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome","volume":"37","author":"Meenakumari","year":"2004","journal-title":"Braz J Med Biol Res"},{"key":"10.4158\/EP14396.RA_bb0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/humrep\/deh580","article-title":"Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome","volume":"20","author":"S\u00f6nmez","year":"2005","journal-title":"Hum Reprod"},{"key":"10.4158\/EP14396.RA_bb0235","first-page":"586","article-title":"Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome [in Chinese]","volume":"39","author":"Liu","year":"2004","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.4158\/EP14396.RA_bb0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jc.2004-1405","article-title":"Flutamide-metformin plus ethinyl-estradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy","volume":"90","author":"Ib\u00e1\u00f1ez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0245","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1210\/jc.2003-031737","article-title":"Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome","volume":"89","author":"Brettenthaler","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0250","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.2003-031780","article-title":"Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study","volume":"89","author":"Ganie","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0255","first-page":"173","article-title":"Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome [in Chinese]","volume":"39","author":"Zhang","year":"2004","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.4158\/EP14396.RA_bb0260","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.fertnstert.2003.08.012","article-title":"Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin","volume":"81","author":"Maciel","year":"2004","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0265","first-page":"745","article-title":"Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome [in Chinese]","volume":"38","author":"Ye","year":"2003","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.4158\/EP14396.RA_bb0270","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","article-title":"Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome","volume":"60","author":"Gambineri","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP14396.RA_bb0275","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1210\/jc.2002-021688","article-title":"Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome","volume":"88","author":"Morin-Papunen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00404-002-0344-1","article-title":"The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue","volume":"268","author":"Ci\u00e7ek","year":"2003","journal-title":"Arch Gynecol Obstet"},{"key":"10.4158\/EP14396.RA_bb0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1071-55760200260-5","article-title":"Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy","volume":"10","author":"Shobokshi","year":"2003","journal-title":"J Soc Gynecol Investig"},{"key":"10.4158\/EP14396.RA_bb0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/humrep\/deg105","article-title":"Sequential treatment of metformin and clomiphene citrate in clomipheneresistant women with polycystic ovary syndrome: a randomized, controlled trial","volume":"18","author":"George","year":"2003","journal-title":"Hum Reprod"},{"key":"10.4158\/EP14396.RA_bb0295","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2002-020997","article-title":"Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study","volume":"88","author":"Morin-Papunen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0300","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-2003-39056","article-title":"Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial","volume":"35","author":"Chou","year":"2003","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP14396.RA_bb0305","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1210\/jc.2002-020776","article-title":"Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels","volume":"87","author":"Pagotto","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0310","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","article-title":"Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiolcyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study","volume":"17","author":"Elter","year":"2002","journal-title":"Hum Reprod"},{"key":"10.4158\/EP14396.RA_bb0315","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1210\/jcem.87.6.8568","article-title":"Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation","volume":"87","author":"Ib\u00e1\u00f1ez","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0320","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0015-0282(01)02941-7","article-title":"Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome","volume":"77","author":"Kocak","year":"2002","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0325","first-page":"1126","article-title":"Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome","volume":"86","author":"Jakubowicz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0330","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0015-0282(00)01675-7","article-title":"Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone","volume":"75","author":"Vandermolen","year":"2001","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0335","first-page":"3161","article-title":"Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study","volume":"85","author":"Morin-Papunen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0340","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1210\/jcem.85.8.6738","article-title":"Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome","volume":"85","author":"Pasquali","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0345","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM199608293350902","article-title":"Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome","volume":"335","author":"Nestler","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14396.RA_bb0350","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/09513590802217027","article-title":"Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome","volume":"24","author":"Wu","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.4158\/EP14396.RA_bb0355","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0360","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.fertnstert.2005.10.042","article-title":"Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome","volume":"85","author":"Khorram","year":"2006","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0365","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/humrep\/17.2.289","article-title":"Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial","volume":"17","author":"Yarali","year":"2002","journal-title":"Hum Reprod"},{"key":"10.4158\/EP14396.RA_bb0370","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2337\/dc08-1681","article-title":"Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study","volume":"32","author":"Rosenson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.4158\/EP14396.RA_bb0375","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.4158\/EP14396.RA_bb0380","first-page":"271","article-title":"Omega-3 acid ethyl esters (Lovaza) for severe hypertriglyceridemia","volume":"33","author":"Koski","year":"2008","journal-title":"Drug Forecast"},{"key":"10.4158\/EP14396.RA_bb0385","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.4158\/EP14396.RA_bb0390","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14396.RA_bb0395","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"10.4158\/EP14396.RA_bb0400","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-142-7-200504050-00011","article-title":"Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians","volume":"142","author":"Snow","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP14396.RA_bb0405","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.4158\/EP14396.RA_bb0410","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0415","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.0.1380269","article-title":"Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome","volume":"138","author":"Diamanti-Kandarakis","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP14396.RA_bb0420","first-page":"139","article-title":"Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14396.RA_bb0425","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0015-0282(99)00208-3","article-title":"Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome","volume":"72","author":"De Leo","year":"1999","journal-title":"Fertil Steril"},{"key":"10.4158\/EP14396.RA_bb0430","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0026-0495(99)90113-0","article-title":"Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome","volume":"48","author":"Glueck","year":"1999","journal-title":"Metabolism"},{"key":"10.4158\/EP14396.RA_bb0435","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0015-0282(98)00011-9","article-title":"Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome","volume":"69","author":"Morin-Papunen","year":"1998","journal-title":"Fertil Steril"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/N02526R0435HGN34.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:30Z","timestamp":1761515910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20356639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1530891X20356639"],"URL":"https:\/\/doi.org\/10.4158\/ep14396.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Insulin Sensitizers on Cardiovascular Risk Factors in Polycystic Ovarian Syndrome: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP14396.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}